Bill Snyder Archive — Page 41 of 121

Illustration of several spherical virus particles with brown textured surfaces and numerous translucent yellow spike-like projections, shown against a dark reddish-brown background.
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

Glowing cyan electrocardiogram waveform with two prominent heartbeat spikes against a dark blue grid background.
September 16, 2021

VUMC team to test personalized acute heart failure treatment

Researchers at Vanderbilt have been awarded a five-year, $4 million federal grant to test whether a personalized medicine strategy will improve outcomes for patients hospitalized with acute heart failure.

Portrait of Cecilia Chung, MD, MPH, smiling and wearing a white blazer over a patterned top.
September 16, 2021

Chung receives early investigator award from ASCPT

Vanderbilt’s Cecilia Chung, MD, MPH, has received the 2022 Leon I. Goldberg Early Investigator Award from the American Society of Clinical Pharmacology and Therapeutics (ASCPT).

Illustration of red blood cells and several white blood cells suspended in a red bloodstream.
September 16, 2021

‘Pre-conditioning’ restores immune tolerance

A treatment targeting T-cell metabolism could reinvigorate immune tolerance mechanisms to combat autoimmune disease and transplant rejection, Vanderbilt researchers discovered.

Green-gloved laboratory worker holds two small tubes containing clear liquid over a blurred lab coat.
September 8, 2021

VUMC antibodies help neutralize two deadly viruses: study

Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.

The team studying tumor suppressor protein p53 includes, from left, Jennifer Pietenpol, PhD, and Lindsay Redman-Rivera.
September 2, 2021

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.